Home Featured Page 158

Featured

Latest

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its...

Looking Forward to Horizons Northwest, This September in Portland

COMPASS Pathways to participate in three upcoming investor events

Optimi Health Provides Progress Report On Year Of Commercialization

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN...

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of...

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

Film Club: Music for Mushrooms

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and Scaling Psychedelic Care

test

Film Club: Music for Mushrooms

Psychedelic Approvals on Track, Advocacy in Flux: A Washington Dispatch on FDA, Election Year and ‘Ibogaine Exceptionalism’

Betty Aldworth & Ismail Ali: MAPS Co-Executive Directors on Leadership, Research, and the Future of Psychedelics

MDMA Enhances Fear Extinction Learning: From Models to Mechanisms

PT352 – Alex Enchin & Ian-Michael Hébert, MA – HOLOS: Returning...

Algernon Pharmaceuticals Reports Positive Results from Full Data Set of its...

Looking Forward to Horizons Northwest, This September in Portland

Looking Forward to Horizons Northwest, This September in Portland

COMPASS Pathways to participate in three upcoming investor events

Optimi Health Provides Progress Report On Year Of Commercialization

FILAMENT HEALTH AND ATMA JOURNEY CENTERS ANNOUNCE 14 SUBJECTS DOSED IN...

Reunion Neuroscience Inc. Announces 2022 Annual General Meeting of Shareholders

Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of...

EDITOR PICKS

What Approval Won’t Solve: Brian Barnett on Ketamine’s Lessons, RVUs, and...

test

Film Club: Music for Mushrooms

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY